FDA Approves New GLP-1 Pill as Ozempic MDL Approaches Make-or-Break Deadlines

The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, 2026 — the first oral GLP-1 weight loss pill that can be taken at any time of day without food or water restrictions. The approval expands a drug class already at the center of one of the fastest-growing mass tort litigations in the country, with 3,363 cases pending in MDL 3094 and critical summary judgment and Daubert deadlines approaching in late April.

Foundayo's commercial launch began April 6 through Eli Lilly's LillyDirect digital pharmacy, with pricing set at $25 per month for commercially insured patients and $149 to $349 per month for self-pay — significantly undercutting existing GLP-1 injectables. The drug was approved in just 50 days under the FDA's National Priority Voucher program, making it the fastest new molecular entity approval since 2002.

What Makes Foundayo Different

Foundayo is the first non-peptide, small-molecule GLP-1 receptor agonist — a fundamentally different chemical structure from the injectable semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) drugs that dominate the market. In the ATTAIN-1 clinical trial of 3,127 adults, participants on the highest dose (36 mg) lost an average of 12.4% body weight — approximately 27 pounds — over 72 weeks.

The drug's key differentiator is convenience. Unlike Novo Nordisk's oral Wegovy pill, which requires 30 minutes of fasting, Foundayo can be taken at any time with or without food. That ease of use is expected to drive significantly wider adoption.

The GLP-1 Drug Class Under Litigation

The GLP-1 class now includes at least nine FDA-approved drugs across two manufacturers:

Novo Nordisk: Ozempic and Rybelsus (semaglutide for diabetes), Wegovy injection and oral pill (semaglutide for weight loss), Victoza and Saxenda (liraglutide)

Eli Lilly: Mounjaro (tirzepatide for diabetes), Zepbound (tirzepatide for weight loss), and now Foundayo (orforglipron for weight loss)

Eli Lilly is already a co-defendant in MDL 3094 for Mounjaro. Foundayo's approval adds another product to the company's GLP-1 portfolio — and another potential source of claims as adoption scales.

The MDL Reaches a Critical Phase

MDL 3094, consolidated before Judge Karen S. Marston in the Eastern District of Pennsylvania, is entering its most consequential stretch. Expert discovery closed in late March 2026, and Daubert motions to exclude expert testimony are due April 28, with summary judgment motions due April 30.

Plaintiffs allege that GLP-1 drugs cause gastroparesis (stomach paralysis), bowel obstruction, necrotizing pancreatitis, gallbladder disease, and aspiration injuries — and that manufacturers failed to adequately warn patients and prescribers. The FDA added a gastroparesis warning to the Ozempic label in October 2025, strengthening plaintiffs' position.

Vision Damage Claims Separated Into New MDL

A July 2024 study published in JAMA Ophthalmology by researchers at Massachusetts Eye and Ear (Harvard-affiliated) found that patients taking semaglutide were 4.28 times more likely to develop nonarteritic anterior ischemic optic neuropathy (NAION) — a condition that can cause sudden, permanent vision loss. Overweight patients on semaglutide faced a 7.64 times higher risk.

The findings prompted over 140 vision-related claims, which were separated into a distinct MDL-3163 in December 2025. First bellwether trials in the main gastroparesis MDL are expected by mid-2026.

A Wrongful Death Raises the Stakes

In March 2026, the family of Marsha Ettinghoff, a 76-year-old woman who died from gastroparesis after six months on Ozempic, filed a wrongful death lawsuit. According to the complaint, her symptoms were initially misdiagnosed as food poisoning before she aspirated and died during transport to a hospital. The case, filed by Motley Rice, adds fatal outcomes to the litigation narrative.

Price Wars Signal Market Pressure

The competitive landscape is shifting rapidly. On February 24, 2026, Novo Nordisk announced it would cut Wegovy list prices by approximately 50% and Ozempic by approximately 35%, effective January 1, 2027. On March 31, the company launched discounted Wegovy subscription plans for self-pay patients at $249 to $329 per month through telehealth providers.

Foundayo's aggressive pricing — $25 per month with insurance versus Wegovy's current $1,300+ list price — is accelerating this race. For the litigation, these pricing dynamics matter: lower prices drive broader adoption, expanding the potential plaintiff pool, while the revenue stakes for defendants remain in the tens of billions.

What This Means for 2026

The Bottom Line

The GLP-1 litigation is entering its most decisive phase just as the drug class is expanding. Foundayo's approval adds a ninth major GLP-1 product to the market, and its ease of use and aggressive pricing virtually guarantee wider adoption. For plaintiff firms, the next 90 days will shape the trajectory of this litigation — from the April Daubert and summary judgment deadlines to the first bellwether trial selections expected by mid-year.

Firms building GLP-1 case inventory need comprehensive medical records spanning multiple specialties. GLP-1 patients typically see primary care physicians, endocrinologists, gastroenterologists, and — in vision damage cases — ophthalmologists. Missing a single provider can mean missing critical evidence.

Sources: FDA, Eli Lilly, MDL Update, JAMA Ophthalmology, Reuters, Novo Nordisk. Internal data based on LlamaLab's analysis of GLP-1-related medical record requests.